Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.

GI perforation is a serious, potentially life-threatening complication that can occur in people with autoimmune diseases; this report highlights that perforation can happen during corticosteroid tapering and that careful...

The work identifies a genetic link (HLA‑DRB1*01:03) to anti‑IL‑10 autoantibodies and describes a small subgroup of IBD patients who may have a distinct immune mechanism driving disease—information that could matter for...

The gut microbiome differed more in pediatric Crohn’s disease and acute pancreatitis than in IBS or healthy kids, suggesting microbial changes are stronger in organic inflammatory disease and could be targets for future...

Lower hospitalization rates suggest upadacitinib may reduce severe disease events that require inpatient care, which matters to patients and clinicians aiming to avoid hospital stays and complications. Large real-world...

If confirmed, a simple blood marker (NLR) plus biopsy results could help identify UC patients at higher risk of relapse despite endoscopic improvement, which might guide monitoring or treatment choices.

The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...

Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.

People with IBD commonly have musculoskeletal pain and need safe short-term pain options. This review suggests selective COX-2 inhibitors may be an option for selected patients in remission when monitored closely, but...

The study identifies a food-processing method (black tea processing) that increased flavonoids and improved outcomes in a mouse model of colitis, suggesting that specific dietary preparations might influence gut...

Phosphatidylcholines are implicated in IBD biology; identifying a gene that regulates PC metabolism could point to new mechanistic targets. If PRKAB1 modulates epithelial lipid metabolism relevant to inflammation, it may...

Cure8 found this source from American journal of therapeutics, but the page could not be read reliably yet. It is tagged for Crohn's disease, Infliximab, and Anti-TNF. Open the original article for the full details.

New, non-invasive biomarkers and AI-driven multi-omic approaches could make diagnosis and treatment of IBD more precise, helping patients avoid invasive tests and improving chances of choosing effective therapies sooner.

The paper suggests a mechanistic link between gut microbial gas production and mitochondrial function, which could be relevant for understanding metabolic stress and inflammation in IBD.

This preclinical study suggests a marine-derived collagen peptide fraction may strengthen intestinal barrier function, reduce oxidative stress, and partially restore gut microbiota in models of colitis — mechanisms...

Prednisone is a commonly used steroid for short-term control of IBD flares; changes or reaffirmations in its FDA label affect prescribing and safety guidance that patients and clinicians rely on.

Identifies features associated with the new international definition of difficult‑to‑treat Crohn’s disease and links DTT status to greater mental fatigue. Biomarker differences (IL‑5, IL‑10) may point to distinct immune...

Fatigue affects many people with Crohn’s even when inflammation looks controlled; recognizing it as a distinct target could change clinic assessments and treatment priorities.

Patients with small-bowel strictures face repeat procedures or surgery; this study suggests endoscopic stricturotomy outcomes differ by whether the stricture is from Crohn’s disease and that a simple blood marker (NLR)...

The study identifies a potential biologic approach (macrophage-derived exosomes) that improved epithelial repair and barrier function in a mouse colitis model, which could inform future therapeutic research for IBD.

Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Alimentary pharmacology &...

Based on the title and source metadata, this appears to be an opinion or commentary related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from European radiology.

The study suggests that being symptom-free doesn’t guarantee the gut’s microbiome, metabolome, or epithelial functions have returned to a healthy state. Diet—especially ultraprocessed-food intake—was linked to persistent...

The work targets oxidative/nitrosative stress and mucosal repair—mechanisms important in IBD—using a novel delivery vehicle that pairs an approved anti-inflammatory drug with catalytic cerium ions. If translated, this...

If hospital-treated infections raise later IBD risk—especially in people with certain immune-related genetic variants—this supports a multi-hit model of IBD and could eventually help identify higher-risk individuals...

The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...

Postoperative recurrence after ileal resection is common in Crohn’s disease; understanding microbial changes linked to recurrence could help explain mechanisms and guide future biomarker development.

The project could reveal a new neuro-immune circuit (IL-17A acting on enteric neurons) that promotes tissue protection during intestinal inflammation, suggesting novel non-immunosuppressive therapeutic targets for IBD.

Understanding how commensal-specific CD8+ T cells are generated and become pathogenic could reveal new mechanisms contributing to IBD, pointing to future therapeutic targets. The project aims to clarify immune–microbiota...

This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...

People with longstanding ulcerative colitis face higher colorectal cancer risk; this project focuses on a specific immune/stromal cell population (ST2+ cells responding to IL-33) that may help explain how chronic...

Bile acids shape immune signaling in the gut, and this project investigates how altered bile acid pools during ileitis could contribute to Crohn’s disease—knowledge that might point to new biomarkers or treatment...

The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.

This is an FDA drug-label record for ustekinumab that lists approved uses for Crohn’s disease and ulcerative colitis and highlights safety precautions (infections, TB screening, malignancy risk, and vaccine...

Based on the title and source metadata, this appears to be a regulatory update related to Ustekinumab, IL-12/23 inhibitor, and Medications. The original article is from DailyMed.

Based on the title and source metadata, this appears to be a regulatory update related to Tofacitinib, JAK inhibitor, and Medications. The original article is from DailyMed.

An FDA label update names risankizumab (SKYRIZI) as a treatment option for adults with moderately to severely active Crohn’s disease and ulcerative colitis and highlights new or emphasized safety monitoring (liver tests,...

This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...

Intestinal fibrosis and strictures remain a major cause of surgery and obstruction in Crohn’s disease, and current anti-inflammatory drugs don’t reliably prevent fibrosis. If microbial choline degradation promotes...

Children with Crohn’s disease have fewer FDA‑approved advanced treatment options than adults, so clinicians and families often must choose among off‑label therapies with limited pediatric evidence.

The FDA label update for tofacitinib lists ulcerative colitis among approved uses and highlights serious safety warnings that are directly relevant to people with IBD considering or taking this oral JAK inhibitor.

This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed...

This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers....

The study could create a human-derived lab model to better understand and treat colitis caused by cancer immunotherapy, and to evaluate IBD drugs for that purpose without compromising tumor control.

FUT enzymes affect mucosal immunity and have been associated with Crohn's disease and other IBDs; understanding their function could reveal new biological mechanisms and future therapeutic targets.

The survey highlights wide variation in how rectal stumps are assessed and managed after colectomy in children with UC, indicating uncertainty and a gap in standardised care that could affect outcomes and follow-up...

The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...

Researchers are exploring plant-derived polysaccharides as potential therapies that might reduce inflammation and protect the intestinal barrier. For people with UC, therapies that reduce pyroptosis and restore...